最新一期业绩显示，2025年三季报，公司实现营业收入2.54亿元，同比减少2.90%；净利润8894.45万 元，同比减少3.66%，销售毛利率73.20%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13超研股份68.9867.387.5498.09亿行业平均 52.1952.084.44109.78亿行业中值40.1437.372.7954.98亿1九安医疗10.2111.560.87192.85亿2康德莱 15.2317.241.3937.13亿3英科医疗15.4517.951.45263.10亿4奥美医疗15.5519.081.8970.36亿5维力医疗 15.7817.571.9938.56亿6安杰思17.2416.041.8947.05亿7新华医疗17.7313.041.1490.21亿8山东药玻 17.7414.391.67135.71亿9奥泰生物17.7717.311.3452.37亿10九强生物18.1714.732.0578.45亿11安图生物 19.3017.742.42211.88亿12三鑫医疗19.6921.173.4948.14亿 来源：市场资讯 资金流向方面，11月2 ...

11月12日，超研股份涨1.45%，成交额8709.84万元。两融数据显示，当日超研股份获融资买入额822.47 万元，融资偿还688.84万元，融资净买入133.63万元。截至11月12日，超研股份融资融券余额合计 9295.43万元。 融资方面，超研股份当日融资买入822.47万元。当前融资余额9272.48万元，占流通市值的6.30%。 融券方面，超研股份11月12日融券偿还100.00股，融券卖出1400.00股，按当日收盘价计算，卖出金额 3.53万元；融券余量9100.00股，融券余额22.96万元。 资料显示，汕头市超声仪器研究所股份有限公司位于广东省汕头市金砂路77号，成立日期1982年11月15 日，上市日期2025年1月22日，公司主营业务涉及专业从事医学影像设备、工业无损检测设备的研发、 生产和销售的国家级重点高新技术企业。主营业务收入构成为：医用超声71.16%，工业超声17.30%， 配附件5.72%，X射线4.56%，其他(补充)1.26%。 截至9月30日，超研股份股东户数1.70万，较上期减少23.90%；人均流通股3438股，较上期增加 39.99%。2025年1月-9月，超 ...

Core Viewpoint - Duople (301528) is a high-tech enterprise specializing in the research, development, production, and sales of non-destructive testing equipment, providing professional solutions for industrial non-destructive testing [1] Group 1: Company Overview - The company offers a comprehensive range of products including industrial non-destructive testing equipment, ultrasonic transducers, and other supporting components [1] - Duople has established a full-chain business system that includes ultrasonic transducers, scanning devices, various types of testing instruments, portable ultrasonic phased array testing equipment, and automated testing systems [1] - The company covers applications across various niche fields, providing solutions and training services [1]

11月3日，超研股份涨1.14%，成交额4630.93万元。两融数据显示，当日超研股份获融资买入额608.35 万元，融资偿还311.34万元，融资净买入297.00万元。截至11月3日，超研股份融资融券余额合计 9382.24万元。 融资方面，超研股份当日融资买入608.35万元。当前融资余额9359.73万元，占流通市值的6.48%。 融券方面，超研股份11月3日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量9100.00股，融券余额22.51万元。 资料显示，汕头市超声仪器研究所股份有限公司位于广东省汕头市金砂路77号，成立日期1982年11月15 日，上市日期2025年1月22日，公司主营业务涉及专业从事医学影像设备、工业无损检测设备的研发、 生产和销售的国家级重点高新技术企业。主营业务收入构成为：医用超声71.16%，工业超声17.30%， 配附件5.72%，X射线4.56%，其他(补充)1.26%。 截至9月30日，超研股份股东户数1.70万，较上期减少23.90%；人均流通股3438股，较上期增加 39.99%。2025年1月-9月，超研股份实现营业收入 ...

Core Insights - ChaoYan Co., Ltd. is a national high-tech enterprise specializing in medical imaging and industrial non-destructive testing equipment, with a competitive market position [1] Group 1: Business Performance - For Q3 2025, ChaoYan reported revenue of 254 million yuan, ranking 34th among 42 companies in the industry, while the industry leader, Mindray Medical, achieved revenue of 25.834 billion yuan [2] - The company's net profit for the same period was 88.9445 million yuan, ranking 19th in the industry, with the top performer, Mindray Medical, reporting a net profit of 7.814 billion yuan [2] Group 2: Financial Ratios - ChaoYan's debt-to-asset ratio was 7.85% in Q3 2025, down from 12.84% year-on-year, significantly lower than the industry average of 27.21%, indicating strong solvency [3] - The company's gross profit margin was 73.20%, an increase from 71.36% year-on-year, and higher than the industry average of 48.67%, reflecting robust profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 23.90% to 17,000, while the average number of circulating A-shares held per shareholder increased by 39.99% to 3,438.65 [5] - The largest circulating shareholder, HuaBao ZhongZheng Medical ETF, held 1.5245 million shares, a decrease of 388,200 shares from the previous period [5]

Core Viewpoint - Chao Yan Co., Ltd. has shown a slight increase in stock price and trading volume, with notable financing activities indicating investor interest and potential growth in the medical imaging and industrial non-destructive testing sectors [1][2]. Financing and Trading Activity - On October 24, Chao Yan Co., Ltd. experienced a stock price increase of 0.52% with a trading volume of 56.81 million yuan. The financing buy-in amounted to 3.27 million yuan, while the financing repayment was 4.04 million yuan, resulting in a net financing outflow of 0.77 million yuan. The total financing and securities balance reached 92.15 million yuan [1]. - The current financing balance is 91.98 million yuan, representing 6.30% of the circulating market value. In terms of securities lending, 1,200 shares were repaid with no shares sold on October 24, leading to a remaining securities lending balance of 6,800 shares valued at 170,100 yuan [1]. Company Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period. The average circulating shares per person increased by 19.98% to 2,456 shares. For the first half of 2025, the company reported a revenue of 184 million yuan, reflecting a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2]. - Since its A-share listing, Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends [3]. Shareholder Composition - As of June 30, 2025, the largest shareholder among the top ten circulating shareholders is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder. The second-largest is Southern Zhongzheng 1000 ETF with 514,500 shares, also a new shareholder. Hong Kong Central Clearing Limited is the fourth-largest shareholder with 470,000 shares, having increased its holdings by 21,600 shares compared to the previous period [3].

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive performance in stock trading and financial results, indicating growth potential in the medical imaging and industrial non-destructive testing equipment sectors [1][2]. Financial Performance - As of June 30, 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders for the same period was approximately 68.45 million yuan, reflecting an 18.5% increase compared to the previous year [2]. Stock Trading Activity - On October 14, 2023, Chao Yan Co., Ltd. saw a stock price increase of 2.24%, with a trading volume of approximately 92.23 million yuan [1]. - The financing buy-in amount for the same day was 6.48 million yuan, while the financing repayment was 6.92 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1]. - The total financing and securities balance as of October 14, 2023, was approximately 95.63 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. Dividend Distribution - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable institutional shareholders include Southern Zhongzheng 1000 ETF and Hong Kong Central Clearing Limited, with significant shareholdings and increases [3].

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive financial performance with a revenue increase of 15% year-on-year and a net profit growth of 18.5% for the first half of 2025, indicating strong operational capabilities and market demand [2]. Financial Performance - For the period from January to June 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, reflecting a year-on-year growth of 15% [2]. - The net profit attributable to the parent company for the same period was approximately 68.45 million yuan, which represents an 18.5% increase compared to the previous year [2]. - Cumulative cash dividends distributed by the company since its A-share listing amount to approximately 43.69 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares held per shareholder increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [2]. Trading Activity - On September 24, 2025, Chao Yan Co., Ltd. saw a stock price increase of 1.52%, with a trading volume of approximately 48.73 million yuan [1]. - The financing buy-in amount for the same day was 2.94 million yuan, while the financing repayment was 10.16 million yuan, resulting in a net financing outflow of 7.22 million yuan [1]. - The total balance of margin trading for Chao Yan Co., Ltd. as of September 24, 2025, was approximately 102 million yuan, accounting for 7.03% of its market capitalization [1].

Core Insights - Duople's revenue for the first half of 2025 reached 79.9851 million yuan, a significant increase of 56.19% year-on-year, while net profit rose by 12.15% to 19.0376 million yuan [3][4] - The company's R&D investment amounted to 22.4146 million yuan, reflecting a year-on-year growth of 40.57%, with R&D accounting for 28.02% of total revenue, highlighting its commitment to innovation and technology [3][4] Revenue Growth Factors - The growth in Duople's performance is primarily attributed to two factors: the recovery of the domestic economy, which has led to the release of delayed equipment purchasing demands, and the company's proactive approach to expanding into new markets such as Africa and Oceania amidst changing overseas trade environments [4][5] Market Expansion Strategies - Duople is actively promoting phased array technology by participating in domestic and international exhibitions, academic forums, and training sessions to enhance its application within the industry [5] - The company is focusing on key sectors such as rail transportation, new energy vehicles, and semiconductors, introducing products like liquid cooling plate immersion detection systems and automated detection systems for target materials to address industry pain points [5] Technological Development - As a core unit in several national R&D projects, Duople is involved in developing high-performance ultrasonic phased array detection equipment to meet complex detection needs in industries such as aerospace and nuclear power [5] - The company aims to leverage its technological advancements and market expansion capabilities to drive innovative applications of non-destructive testing equipment in high-end industrial sectors, enhancing its competitiveness in the global market [5]

Major Events - The actual controller, chairman, and CEO of Juran Smart Home, Wang Linpeng, passed away on July 27, 2025. He held a total of 43.93% of the company's shares. The board has appointed Wang Ning as the acting chairman and CEO [3] - Shennong Group has decided to terminate its plan for a specific stock issuance for 2024 due to changes in market conditions and will withdraw its application [5] - Xizhuang Co. plans to establish a joint venture to engage in sustainable aviation fuel-related business with a registered capital of 5 million yuan, where Xizhuang will contribute 1.1 million yuan [6] - Shandong Gold's subsidiary, Shanjin International, intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [7] - Luopusi Co. plans to acquire a 38.38% stake in Wuhan Senfurui Technology Co. for 8.82 million yuan [8] - Hengxin Life plans to invest no more than 505 million yuan to build a biodegradable product production base in Hefei, Anhui Province [9] - Hetai Machinery announced it has not participated in the Yaxi project construction, which is still in the early stages [10] - Kaishan Co. plans to acquire a 5% stake in SMGP for 3 million USD, resulting in full ownership of the company [11] - Ruian New Materials intends to terminate its raw material project due to uncertainties in the second phase of construction [12] - Zhonghua Equipment plans to purchase 100% equity of Yiyang Rubber Machine and Beihua Machine, with stock resuming trading on July 29, 2025 [13] - Huizhou Intelligent announced that a board member has resigned due to being identified as a dishonest executor [14] - Xuefeng Technology plans to acquire a 51% stake in Shengshi Putian for 154 million yuan [15][16] - Top Cloud Agriculture intends to establish a wholly-owned subsidiary focused on artificial intelligence technology with an investment of 20 million yuan [17] - Shiming Technology's actual controller is under detention, but it does not affect the company [18] - Dahua Intelligent is under investigation by the CSRC for suspected information disclosure violations [19] - Dalian Shengya plans to change its controlling shareholder and will resume trading on July 29, 2025 [20] - Fashilong has signed a share transfer agreement and will resume trading on July 29, 2025 [21] - Guangku Technology plans to acquire control of Anjie Xun, with trading suspended from July 29, 2025 [22] - Tianyi Co. has been selected as a candidate for a procurement project by China Mobile [23] - Zhongtung High-tech's subsidiary plans to implement a 1.4 billion drill bit intelligent manufacturing project with an investment of 178 million yuan [24] Performance Overview - WuXi AppTec reported a net profit of 8.561 billion yuan for the first half of 2025, a year-on-year increase of 101.92% [25] - Sujiao Science and Technology's net profit decreased by 39.54% year-on-year, with a revenue of 1.776 billion yuan [26] - Aide Biology achieved a net profit of 189 million yuan, up 31.41% year-on-year [27] - Huicheng Environmental's net profit dropped by 85.63% year-on-year, with a revenue of 564 million yuan [28] - Haida Group reported a net profit of 2.639 billion yuan, a year-on-year increase of 24.16% [30] Major Contracts - Weiye Co. won a construction project worth approximately 522 million yuan [31] - Fosun Pharma's subsidiary signed a licensing agreement for a drug targeting Alzheimer's disease [32] - Huafeng Aluminum plans to sign a raw material purchase contract with Yulin New Materials, with an estimated total amount exceeding 7.2 billion yuan [33] Shareholding Changes - Suneng Co. plans to reduce its stake by up to 1% [34] - Shengyang Technology's shareholder plans to reduce its stake by up to 1% [35] - Jingquan Hua's shareholder plans to reduce its stake by up to 1% [36] - Tigermed plans to reduce its stake by up to 3% [38] Financing Activities - Huhua Co. plans to raise no more than 586 million yuan through a private placement for various projects [39]